TRAVERE THERAPEUTICS INC (TVTX)
US89422G1076 - Common Stock
Taking everything into account, TVTX scores 2 out of 10 in our fundamental rating. TVTX was compared to 588 industry peers in the Biotechnology industry. TVTX may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, TVTX is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year TVTX has reported negative net income.
TVTX had a negative operating cash flow in the past year.
In the past 5 years TVTX always reported negative net income.
TVTX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -14.12%, TVTX belongs to the top of the industry, outperforming 87.33% of the companies in the same industry.
With a decent Return On Equity value of -55.47%, TVTX is doing good in the industry, outperforming 64.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.12% | ||
| ROE | -55.47% | ||
| ROIC | N/A |
ROA(3y)-26.24%
ROA(5y)-26.16%
ROE(3y)-254.76%
ROE(5y)-182.13%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TVTX has a better Gross Margin (92.12%) than 94.18% of its industry peers.
In the last couple of years the Gross Margin of TVTX has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for TVTX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 92.12% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.68%
GM growth 5Y-0.96%
2. Health
2.1 Basic Checks
TVTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TVTX has been increased compared to 1 year ago.
Compared to 5 years ago, TVTX has more shares outstanding
The debt/assets ratio for TVTX has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -2.30, we must say that TVTX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -2.30, TVTX perfoms like the industry average, outperforming 49.83% of the companies in the same industry.
A Debt/Equity ratio of 1.88 is on the high side and indicates that TVTX has dependencies on debt financing.
TVTX has a Debt to Equity ratio of 1.88. This is amonst the worse of the industry: TVTX underperforms 81.85% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.88 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.3 |
ROIC/WACCN/A
WACC5.71%
2.3 Liquidity
TVTX has a Current Ratio of 3.47. This indicates that TVTX is financially healthy and has no problem in meeting its short term obligations.
TVTX's Current ratio of 3.47 is on the low side compared to the rest of the industry. TVTX is outperformed by 61.13% of its industry peers.
TVTX has a Quick Ratio of 3.41. This indicates that TVTX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of TVTX (3.41) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.47 | ||
| Quick Ratio | 3.41 |
3. Growth
3.1 Past
TVTX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -5.26%.
Looking at the last year, TVTX shows a small growth in Revenue. The Revenue has grown by 6.79% in the last year.
Measured over the past years, TVTX shows a decrease in Revenue. The Revenue has been decreasing by -2.42% on average per year.
EPS 1Y (TTM)-5.26%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q0%
Revenue 1Y (TTM)6.79%
Revenue growth 3Y-9.86%
Revenue growth 5Y-2.42%
Revenue growth Q2Q-19.35%
3.2 Future
The Earnings Per Share is expected to grow by 17.79% on average over the next years. This is quite good.
TVTX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 30.19% yearly.
EPS Next Y29.51%
EPS Next 2Y26.97%
EPS Next 3Y25.56%
EPS Next 5Y17.79%
Revenue Next Year10.98%
Revenue Next 2Y25.98%
Revenue Next 3Y31.02%
Revenue Next 5Y30.19%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for TVTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TVTX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as TVTX's earnings are expected to grow with 25.56% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.97%
EPS Next 3Y25.56%
5. Dividend
5.1 Amount
No dividends for TVTX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TRAVERE THERAPEUTICS INC
NASDAQ:TVTX (4/26/2024, 7:21:08 PM)
After market: 5.26 0 (0%)5.26
-0.13 (-2.41%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap400.34M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.12% | ||
| ROE | -55.47% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 92.12% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.18
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.88 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.47 | ||
| Quick Ratio | 3.41 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-5.26%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y29.51%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)6.79%
Revenue growth 3Y-9.86%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y